ATQP Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Vericel Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.60 |
| 52 Week High | US$59.50 |
| 52 Week Low | US$35.80 |
| Beta | 1.79 |
| 1 Month Change | -22.96% |
| 3 Month Change | -23.67% |
| 1 Year Change | 4.52% |
| 3 Year Change | 34.19% |
| 5 Year Change | 450.99% |
| Change since IPO | 66.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATQP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.7% | 3.1% | -0.5% |
| 1Y | 4.5% | -6.0% | 15.5% |
Return vs Industry: ATQP exceeded the German Biotechs industry which returned -5.8% over the past year.
Return vs Market: ATQP underperformed the German Market which returned 15.5% over the past year.
Price Volatility
| ATQP volatility | |
|---|---|
| ATQP Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: ATQP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ATQP's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 357 | Nick Colangelo | www.vcel.com |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014.
Vericel Corporation Fundamentals Summary
| ATQP fundamental statistics | |
|---|---|
| Market cap | €2.08b |
| Earnings (TTM) | €9.52m |
| Revenue (TTM) | €217.99m |
218.8x
P/E Ratio9.6x
P/S RatioIs ATQP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATQP income statement (TTM) | |
|---|---|
| Revenue | US$237.22m |
| Cost of Revenue | US$65.12m |
| Gross Profit | US$172.11m |
| Other Expenses | US$161.75m |
| Earnings | US$10.36m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 72.55% |
| Net Profit Margin | 4.37% |
| Debt/Equity Ratio | 0% |
How did ATQP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 12:10 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vericel Corporation is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |